JRSM Cardiovascular Disease · Oct 7, 2026
The role of aldosterone synthase inhibitors in hypertension: A systematic review and meta-analysis
By Kashyap VK, Asghar A, Mathew C et al.
BACKGROUND: Prior meta-analyses of aldosterone synthase inhibitors (ASIs) for hypertension were limited by heterogeneous evidence and incomplete safety assessment. New randomised controlled trials (RCTs), including BaxHTN, required an updated synthesis. METHODS: MEDLINE, PubMed, Embase, and Cochrane CENTRAL were searched through January 2026 for placebo-controlled RCTs of ASIs for hypertension. Random-effects models pooled mean differences in systolic and diastolic blood pressure (BP) and risk ratios (RRs) for safety, with 95% confidence intervals (CIs). Principal systolic BP combined office and 24-h ambulatory measurements; office-only analysis was post hoc. RESULTS: Nine RCTs (10 independently randomised cohorts; 3595 participants) were included. ASIs reduced systolic BP (mean difference (MD) -6.84 mmHg; 95% CI -8.76 to -4.93) and diastolic BP (MD -2.99 mmHg; 95% CI -4.22 to -1.76). Office-only systolic BP results were similar (MD -6.64 mmHg; 95% CI -8.97 to -4.32). Intermediate- and high-dose estimates were numerically greater than the low-dose estimate, but interaction was nonsignificant (P = 0.25). ASIs increased hyperkalaemia (RR 2.74; 95% CI 1.59-4.71), hyponatraemia (RR 1.81; 95% CI 1.11-2.95), hypotension (RR 2.76; 95% CI 1.29-5.93), and at least one adverse event (RR 1.22; 95% CI 1.05-1.42). Serious adverse events did not differ significantly (RR 0.98; 95% CI 0.59-1.62). Certainty was high for BP and at least one adverse event and moderate for other safety outcomes. CONCLUSION: ASIs provide clinically meaningful short-term BP reduction in uncontrolled or resistant hypertension but increase electrolyte abnormalities, hypotension, and adverse events. Monitoring is warranted; long-term cardiovascular, renal, and safety outcomes remain uncertain.
doi.org/10.1177/20480040261496108PubMed 43036369Interventions